Valsartan, Losartan, and Irbesartan: Contamination and Legal Action
The Carcinogenic Contamination
Meyer Wilson is pursuing claims related to certain batches of Valsartan, Losartan, and Irbesartan, which were contaminated with N-nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA), known human carcinogens, but were still sold to US consumers for years. These contaminated drugs were widely prescribed to treat high blood pressure and other cardiovascular conditions, putting countless patients at risk of developing cancer.
NDMA and NDEA: Potent Carcinogens
NDMA and NDEA are highly potent carcinogenic compounds identified as “cohorts of concern” by regulatory agencies due to their ability to cause genetic mutations. These N-Nitroso compounds serve no legitimate function aside from inducing cancer in laboratory animals. Exposure to these substances, even at low levels, can significantly increase the risk of various types of cancer.
Manufacturers’ Negligence
The contamination allegedly resulted from systemic quality assurance failings at manufacturing facilities in China and India operated by Zhejiang Huahai Pharmaceuticals, Mylan Pharmaceuticals, Teva Pharmaceuticals, Hetero Labs, Torrent Pharmaceuticals, Aurobindo Pharmaceuticals and others. These companies failed to implement proper safety protocols and quality control measures, leading to the widespread distribution of contaminated drugs.
FDA Recalls and Import Alerts
In 2018, upon discovering these companies had been manufacturing and selling generic products containing carcinogens for years, the FDA initiated an unprecedented recall for all unexpired batches and placed many facilities on import alert, preventing their products from entering the United States. However, by that time, countless patients had already been exposed to the contaminated drugs, putting their health at risk.
Meyer Wilson’s Legal Efforts
Layne Hilton, Lead Counsel in Meyer Wilson’s Mass Torts practice, was appointed to the Plaintiffs’ Steering Committee for the In re Valsartan, Losartan and Irbesartan Products Liability Litigation. She has been integrally involved in various aspects of the case, including taking depositions of key corporate witnesses,, briefing, and arguing discovery issues. Meyer Wilson is committed to holding the responsible parties accountable and securing justice for those affected by the contaminated drugs.
Potential Claims
The plaintiffs seek recovery for economic losses, medical monitoring costs, or personal injuries suffered from developing certain cancers due to ingesting these defective products. Individuals who have been diagnosed with cancer after taking contaminated Valsartan, Losartan, or Irbesartan may be eligible to file a claim against the manufacturers if they suffer from the following cancers:
- Bladder Cancer
- Blood Cancer
- Breast Cancer
- Colorectal/Intestinal Cancer
- Esophageal Cancer
- Gastric Cancer
- Kidney Cancer
- Liver Cancer
- Lung Cancer
- Pancreatic Cancer
- Prostate Cancer
- Uterine Cancer
Contact Meyer Wilson
If you developed cancer after consuming contaminated Valsartan, Losartan, or Irbesartan, contact Meyer Wilson at 866-938-2021 to discuss a potential claim. Their experienced legal team is dedicated to fighting for the rights of those affected by this devastating contamination scandal.
